COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Photodynamic Therapy With Verteporfin for Corneal Neovascularization

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00471406
Recruitment Status : Completed
First Posted : May 9, 2007
Last Update Posted : October 17, 2008
Information provided by:
Chonnam National University Hospital

Brief Summary:

Purpose: To investigate the efficacy of photodynamic therapy with verteporfin for the treatment of patients with corneal neovascularization.

Design: Prospective, non-comparative case series. Participants: Eighteen eyes of 18 patients with stable corneal neovascularization who were refractory to conventional treatment.

Methods: The patients were treated with photodynamic therapy with verteporfin (6 mg/m2). Five patients were treated following penetrating keratoplasty, and 2 patients were treated before penetrating keratoplasty. Best corrected visual acuity and anterior segment photography were performed before and after treatment. The length of cumulative blood vessels and area of corneal neovascularization were measured.

Main outcome measures: Vascular occlusion, best corrected visual acuity, cumulative blood vessel length, and corneal neovascularization area.

Condition or disease Intervention/treatment Phase
Corneal Neovascularization Procedure: Photodynamic Therapy with Verteporfin Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by the National Library of Medicine

Drug Information available for: Verteporfin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patients with clinically stable corneal neovascularization who were not improved after treatment with 1% prednisolone acetate eyedrops instilled 4 times a day for at least 1 month

Exclusion Criteria:

  • Individuals who had active keratitis with vessel proliferation, uncontrolled inflammation, active hepatitis or clinically significant liver disease, or porphyria or other porphyrin sensitivity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00471406

Sponsors and Collaborators
Chonnam National University Hospital
Layout table for investigator information
Study Director: Kyung chul Yoon, MD Chonnam natianl university hospital

Layout table for additonal information Identifier: NCT00471406    
Other Study ID Numbers: CPDT-0001
First Posted: May 9, 2007    Key Record Dates
Last Update Posted: October 17, 2008
Last Verified: October 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Corneal Neovascularization
Neovascularization, Pathologic
Pathologic Processes
Corneal Diseases
Eye Diseases
Photosensitizing Agents
Dermatologic Agents